Inspira Tech Study Shows 100% Prevention of Bloodstream Infection Bacteria
Ticker: IINNW · Form: 6-K · Filed: Apr 10, 2024 · CIK: 1837493
| Field | Detail |
|---|---|
| Company | Inspira Technologies Oxy B.H.N. LTD (IINNW) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: medical-devices, research-results, infection-prevention
TL;DR
Inspira's new tech stops deadly bacteria cold in lab tests - big win for infection prevention!
AI Summary
On April 10, 2024, Inspira Technologies Oxy B.H.N. Ltd. announced positive in vitro study results for its Inspira™ and Ennocure technology. The study demonstrated a 100% prevention rate against bacterial growth that causes bloodstream infections, a significant finding for the medical device company.
Why It Matters
This study's success could lead to a breakthrough in preventing life-threatening bloodstream infections, potentially improving patient outcomes and reducing healthcare costs.
Risk Assessment
Risk Level: medium — While the in vitro results are promising, they are preliminary and do not guarantee success in human clinical trials or market adoption.
Key Numbers
- 100% — Prevention Rate (Effectiveness against bacterial growth causing bloodstream infections in vitro)
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- April 10, 2024 (date) — Announcement date
- Inspira™ and Ennocure (product) — Technology studied
FAQ
What specific bacteria were tested in the study?
The filing does not specify the exact bacterial strains tested, only that they cause bloodstream infections.
What is the next step for the Inspira™ and Ennocure technology after these in vitro results?
The filing does not detail the next steps, but typically such results would lead to further testing, potentially including in vivo or clinical trials.
What is the primary application of Inspira™ and Ennocure technology?
The technology is being studied for its potential to prevent bacterial growth that causes bloodstream infections.
When was this press release issued?
The press release was issued on April 10, 2024.
Is this a 20-F or 40-F filing?
This is a Form 6-K filing, and the company indicates it files annual reports under Form 20-F.
Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 8.7 · Accepted 2024-04-10 08:50:28
Filing Documents
- ea0203633-6k_inspira.htm (6-K) — 11KB
- ea020363301ex99-1_inspira.htm (EX-99.1) — 14KB
- 0001213900-24-031743.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: April 10, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2